Xofigo, Provenge, Zytiga & Xtandi

New Therapies for Treating Advanced Prostate Cancer

Over the last three years there have been significant developments in new therapies for the treatment of advanced prostate cancer. What was once a difficult cancer to treat with limited outcomes is now more effectively managed offering improved survival rates over several years.


UCA is pleased to offer the FDA approved prostate cancer treatment Xofigo – a bone targeting intravenous injection of a radioactive material that treats metastatic prostate cancer resistant to medical or surgical treatments.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

What Is Xofigo Used for?

Xofigo is an intravenous injection of a radioactive material to treat prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to your bones with symptoms, but not to other parts of your body. The medical term for this condition is metastatic castration-resistant prostate cancer, or mCRPC.

How does it work?

Xofigo is injected into a vein. From your bloodstream, the radioactive material in Xofigo (Ra-223 dichloride) goes directly to your bones.

The body treats Xofigo like calcium. The drug is taken into the bone, especially where there are cancer cells. It then destroys tissue cells in a very small area around the bone. This means it will have only a small effect on normal cells in the area.

For more information about Xofigo, please visit the website www.xofigo.com.


Provenge takes the patient’s own immune cells and reprograms them to attack the advanced prostate cancer. This process delivers a treatment specifically designed for each patient. In the clinical trials men treated with Provenge lived longer than men not treated with the drug.

How It Works

Provenge helps the body to attack advanced prostate cancer cells by jumpstarting immune cells already in the body. Unlike preventive vaccines, which protect people from developing particular diseases, Provenge is a therapeutic vaccine that is given to people who have already developed prostate cancer. The vaccine is produced by removing some of a patient’s white blood cells, then exposing them to a protein from prostate cancer cells and a stimulatory molecule. This process primes the white cells to attack prostate cancer when they are re-injected into the body.

For more information about Provenge, please visit the website www.provenge.com

Zytiga & Xtandi

In addition, UCA also offers oral agents Zytiga and Xtandi that kill cancer cells while sparing healthy cells. These treatments are FDA approved and can significantly extend survival and improve the quality of life for patients.


How ZYTIGA Works

You may be aware that the male body naturally produces hormones called androgens. The most well-known androgen in men is testosterone. For men with mCRPC, androgens play a role in fueling the tumor. While not the only source, androgen is produced primarily in the testes and some is also produced by the adrenal glands, which are located above the kidneys. We know now that the tumor itself is also a source of androgen production. While there are other key factors that contribute to the disease, androgen is one such factor. Reducing the production of androgen is key in helping you and your doctor manage your illness.

As such, Zytiga works by targeting the protein cytochrome, which plays a significant role in testosterone production. Unlike other hormone therapies for prostate cancer, Zytiga is able to reduce the production of testosterone from the three main sources: the adrenal glands, the testes, and the prostate tumor.

For more information about Zytiga, please visit the website www.zytiga.com.


How Xtandi Works

Androgens are a group of hormones, which includes testosterone. Xtandi is an androgen receptor inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.

For more information about Xtandi, please visit the website https://www.xtandi.com/what-is-xtandi.